GRPR and breast cancer: In 2016, two studies from the same group reported the development of the heterobivalent compound Lys1(α,γ-Folate)-Lys3-DOTA-BBN(1–14) (Figure 5, 5) for theranostic applications of BC expressing both FR and GRPR.